secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0000950170-24-019754
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences reports Q4/FY2023 net loss; $487M pro-forma cash; bezuclastinib trials on track
--------------------------------------------------------------------------------

- Q4 2023 net loss $54.4M; FY2023 net loss $192.4M (up from $140.2M YoY); R&D expenses $173.8M for 2023.
- Cash $273.2M at Dec 31, 2023; $225M PIPE closed Feb 2024 at $7.50/share (37% premium); pro-forma $487M funds into 2027.
- Three registration-directed bezuclastinib trials enrolling: SUMMIT (NonAdvSM), APEX (AdvSM), PEAK (GIST); topline results expected in 2025.
- SUMMIT Part 1b data: 51% mean TSS improvement, 70% of patients with ≥50% improvement; 100 mg RP2D selected.
- PEAK lead-in: 33% confirmed ORR in 2nd-line GIST; bezuclastinib+sunitinib combination well-tolerated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000095017024019754/0000950170-24-019754-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000095017024019754/cogt-20240226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-019754

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer